clinical trial · NCT06309277
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
Gilgamesh Pharmaceuticals·phase2·completed·n = 46
Major Depressive DisorderGM-1020
brief summary
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.
started
Feb 1, 2024
primary completion
Mar 4, 2025
completion
Mar 27, 2025
last updated
Dec 16, 2025
official title
A Two-Part Controlled Clinical Study to Evaluate Safety, Tolerability, Response, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of GM-1020 in Patients With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol